Jansitin

Sitagliptin, the active ingredient in Jansitin, is a dipeptidyl peptidase-4 (DPP‑4) inhibitor presented as a strength/form for oral use. It treats type 2 diabetes mellitus in adults by improving glycemic control.

GNH USA supplies Jansitin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jansitin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus, acting on the incretin pathway to improve blood glucose regulation. - Type 2 diabetes mellitus (monotherapy): lowers HbA1c and fasting glucose when used with diet and exercise. - Combination therapy with metformin: enhances glycemic control in patients inadequately controlled on metformin alone. - Adjunct to insulin therapy: may improve overall glucose management when added to insulin regimens.

Adverse reactions to Jansitin may vary in frequency and severity.

Common Side Effects: - Nasopharyngitis: mild inflammation of the upper airway. - Headache: transient mild to moderate pain. - Upper respiratory tract infection: symptoms of cough and congestion. - Gastrointestinal upset: nausea, abdominal discomfort. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: including rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: blistering skin disorder. - Severe joint pain: unexplained arthralgia that may be disabling.

Before initiating Jansitin, consider the following safety measures. - Renal impairment: dose adjustment may be required based on creatinine clearance. - Hepatic disease: use with caution in patients with liver dysfunction. - History of pancreatitis: avoid use due to potential recurrence. - Concomitant insulin or sulfonylureas: monitor for hypoglycemia. - Pregnancy and lactation: safety not established; consult prescriber. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Jansitin may interact with other medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure. - Co‑administration with insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycemia. - Drugs causing severe hypersensitivity reactions: may exacerbate allergic responses.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of sitagliptin. - ACE inhibitors: monitor blood pressure when combined. - Warfarin: periodic INR checks recommended.